期刊
EUROPEAN HEART JOURNAL
卷 36, 期 26, 页码 1651-U22出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehv123
关键词
Transcatheter mitral intervention; Transcatheter mitral repair; Transcatheter mitral implantation
资金
- Valtech Cardio
- Abbott Vascular
- Medtronic
- BSC
- MValve
- Micardia
- Edwards
- WL Gore
- St. Jude
- Astra Zeneca
- Boston Scientific
- Gore
- Atritech
- AGA Medical
- St Jude Medical
- Circulite
- Coherex
- Biosense Webster
- Stereotaxis
- Cardiofocus
- Mitralign
- BMDSys
- ACT
- Maya
- Apama
- Topera
- Recor
- Endosense
- SynapticMed
- CardiacImplants
- Biotronik
- AGA
- AstraZeneca
- Bayer
- Berlin Chemie
- Biotronic
- BMS
- Boehringer Ingelheim
- Daiichi Sankyo
- Cordis
- Novartis
- Pfizer
- Sanofi Aventis
Transcatheter mitral interventions has been developed to address an unmet clinical need and may be an alternative therapeutic option to surgery with the intent to provide symptomatic and prognostic benefit. Beyond MitraClip therapy, alternative repair technologies are being developed to expand the transcatheter intervention armamentarium. Recently, the feasibility of transcatheter mitral valve implantation in native non-calcified valves has been reported in very high-risk patients. Acknowledging the lack of scientific evidence to date, it is difficult to predict what the ultimate future role of transcatheter mitral valve interventions will be. The purpose of the present report is to review the current state-of-the-art of mitral valve intervention, and to identify the potential future scenarios, which might benefit most from the transcatheter repair and replacement devices under development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据